A simple and cost-effective HPLC-UV method for the detection of levetiracetam in plasma/serum of patients with epilepsy

被引:16
作者
Engelbrecht, Lynette [1 ]
Grobler, C. J. [2 ]
Rheeders, Malie [1 ]
机构
[1] North West Univ, Sch Pharm Pharmacol, Clin Pharmacokinet Lab, Potchefstroom, South Africa
[2] Vaal Univ Technol, Dept Hlth Sci, Vanderbijlpark, South Africa
关键词
different blood collection tubes; epilepsy; HPLC; human plasma; serum; levetiracetam; TANDEM MASS-SPECTROMETRY; NEWER ANTIEPILEPTIC DRUGS; CHROMATOGRAPHY; PERFORMANCE; PHARMACOKINETICS; BLOOD; SERUM;
D O I
10.1002/bmc.3969
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple, fast and cost-effective method was developed and validated for the determination of levetiracetam (LEV) in plasma/serum of patients using high performance liquid chromatography (HPLC) with ultraviolet detection. The stability of LEV plasma/serum samples over time and in different blood collection tubes was evaluated. Serum/plasma samples were deproteinized by methanol spiked with the internal standard, gabapentin. HPLC was carried out on a Venusil XBP C-18, 250x4.6mm, 5m column, at a flow rate of 1.0mL/min and with mobile phase consisting of 50mm potassium dihydrogen phosphate-acetonitrile at a pH of 5.5. The UV detector was set at 205nm and 10L was injected. Total runtime was 15min. Calibration curves were linear (correlation coefficient=0.999) over a concentration range of 1-60g/mL. Relative standard deviation values for both the inter-day and intra-day precision and accuracy were <5% for the concentration range. The influence of different collection tubes and the effect of time on the stability of LEV was investigated. These factors may cause inaccuracies owing to drug-protein binding and interference in the matrix. This method is simple, fast, cost-effective, reliable and accurate with minimal sample preparation for daily routine use in therapeutic drug monitoring.
引用
收藏
页数:9
相关论文
共 32 条
[21]   Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies [J].
Patsalos, Philip N. ;
Berry, David J. ;
Bourgeois, Blaise F. D. ;
Cloyd, James C. ;
Glauser, Tracy A. ;
Johannessen, Svein I. ;
Leppik, Ilo E. ;
Tomson, Torbjoern ;
Perucca, Emilio .
EPILEPSIA, 2008, 49 (07) :1239-1276
[22]   In situ metabolism of levetiracetam in blood of patients with epilepsy [J].
Patsalos, Philip N. ;
Ghattaura, Sandirup ;
Ratnaraj, Neville ;
Sander, Josemir W. .
EPILEPSIA, 2006, 47 (11) :1818-1821
[23]   Clinical pharmacokinetics of levetiracetam [J].
Patsalos, PN .
CLINICAL PHARMACOKINETICS, 2004, 43 (11) :707-724
[24]  
POONGOTHAI S., 2011, International Journal of PharmTech Research, V3, P1023
[25]  
PRABU S L., 2012, Applied Biological Engineering - Principles and Practice, P470
[26]   High-performance liquid chromatographic determination of Levetiracetam in human plasma: comparison of different sample clean-up procedures [J].
Pucci, V ;
Bugamelli, F ;
Mandrioli, R ;
Ferranti, A ;
Kenndler, E ;
Raggi, MA .
BIOMEDICAL CHROMATOGRAPHY, 2004, 18 (01) :37-44
[27]   Analysis of the antiepileptic drug keppra by capillary electrophoresis [J].
Shihabi, ZK ;
Oles, K ;
Hinsdale, M .
JOURNAL OF CHROMATOGRAPHY A, 2003, 1004 (1-2) :9-12
[28]  
Srinivasu K., 2008, ORIENTAL J CHEM, V24, P1013
[29]   Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs) [J].
Stepanova, Daria ;
Beran, Roy G. .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2014, 23 (05) :371-376
[30]  
US Food and Drug Administration, 2015, PRESCR MED LEV